Jefferies analyst, David Steinberg, cut his PT on Valeant Pharmaceuticals (NYSE: VRX) to meet lowered guidance. Q1 revs exceeded ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE